Petersen, I., Schirmacher, P., Warth, A., & Lasitschka, F. (2017). EGFR immunohistochemistry as biomarker for antibody-based therapy of squamous NSCLC: Experience from the first ring trial of the German Quality Assurance Initiative for Pathology (QuIP®). Pathology, research and practice, 213(12), . https://doi.org/10.1016/j.prp.2017.09.021
Chicago-Zitierstil (17. Ausg.)Petersen, Iver, Peter Schirmacher, Arne Warth, und Felix Lasitschka. "EGFR Immunohistochemistry as Biomarker for Antibody-based Therapy of Squamous NSCLC: Experience from the First Ring Trial of the German Quality Assurance Initiative for Pathology (QuIP®)." Pathology, Research and Practice 213, no. 12 (2017). https://doi.org/10.1016/j.prp.2017.09.021.
MLA-Zitierstil (9. Ausg.)Petersen, Iver, et al. "EGFR Immunohistochemistry as Biomarker for Antibody-based Therapy of Squamous NSCLC: Experience from the First Ring Trial of the German Quality Assurance Initiative for Pathology (QuIP®)." Pathology, Research and Practice, vol. 213, no. 12, 2017, https://doi.org/10.1016/j.prp.2017.09.021.